Anti-CGRP Antibodies: 2-Year Migraine Relief Insights

Research Summary

In a study published in Neurology, researchers explored the long-term effectiveness of anti-CGRP monoclonal antibodies in treating migraines over two years. The EUREkA cohort study followed patients to assess how well these treatments worked and what factors influenced their continued use. Results showed that 73% of participants experienced a significant reduction in migraine days per month. Additionally, 65% of patients continued using the treatment throughout the study period, highlighting its tolerability and effectiveness. The study emphasizes the potential of anti-CGRP therapies as a sustainable option for long-term migraine management, offering hope for those seeking lasting relief from chronic migraines.

Study Details

📄 Title: Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.

👥 Research Team: Caronna E et al.

📚 Published In: Neurology

📅 Publication Date: 2026 Jun 23

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.